Arvinas
New Haven, Connecticut, United States · Biotechnology, Health Care, research
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein deg
Key facts
- Headquarters
- New Haven, Connecticut, United States
- Employees
- 430
- Industries
- Biotechnology, Health Care, research
- Status
- Public (ARVN)
- Website
- arvinas.com
- Company page
Recent activity at Arvinas
- : Arvinas, Inc. Begins Search for New Chief Medical Officer
- : Arvinas Enters License Agreement with Rigel Pharmaceuticals (date Fundz recorded it)
- : SEC 8-K (7.01): On November 3, 2026, Arvinas, Inc. updated its corporate presentation and made it available on the Events and Presentations page under the Investors and Media section of the Company’s website. This presentation aims to provide important information to investors, highlighting key business developments and strategies for the upcoming quarters. The filing includes a copy of the Company's presentation as Exhibit 99.2, which is incorporated by reference, although it is specified that the information shall not be deemed 'filed' for purposes of the Exchange Act. This proactive communication is essential for maintaining transparency with stakeholders.
- : SEC 8-K (5.07): On June 24, 2026, Arvinas, Inc. conducted its annual meeting of stockholders where two Class II directors, Leslie V. Norwalk, Esq. and Randy Teel, Ph.D., were elected to serve until the 2029 annual meeting. The election results showed 33,199,341 votes for Leslie V. Norwalk, Esq., reflecting significant shareholder support. This change may impact the strategic direction and governance of the company as these directors will shape future decisions over the next three years.
- : SEC 8-K (5.02): On June 22, 2026, Arvinas, Inc. announced the departure of Dr. Noah Berkowitz, M.D., Ph.D., the chief medical officer, effective July 3, 2026. Dr. Berkowitz will continue in his role until that date before pursuing other opportunities. The company is actively seeking a new chief medical officer to fill the position. A separation agreement and release of claims was also established on June 22, 2026, outlining terms related to Dr. Berkowitz’s departure.
- : SEC 8-K (5.02): On June 22, 2026, Arvinas, Inc. announced the departure of its chief medical officer, Dr. Noah Berkowitz, effective July 3, 2026. The company entered into a separation agreement with Dr. Berkowitz on the same day, which entitles him to severance benefits that include nine months of continued salary, health coverage premium payments, and accelerated vesting of certain restricted stock units (RSUs). The RSUs subject to acceleration will vest before May 9, 2027, while other RSUs will be forfeited. This decision is part of the company's strategic move as they begin the search for a new chief medical officer to fill the position.
- : SEC 8-K (8.01):
- : SEC 8-K (8.01):
- : SEC 8-K (1.01): On May 11, 2026, Arvinas, Inc. along with its subsidiaries and Pfizer Inc. entered into a License Agreement with Rigel Pharmaceuticals, granting Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant), an estrogen receptor degrader approved for treating certain types of breast cancer. Rigel will pay a one-time upfront fee of $70.0 million, along with potential additional payments up to $320.0 million based on meeting future milestones and tiered royalties. The agreement allows Rigel to sublicense rights for development outside the U.S., while Arvinas and Pfizer will continue their current development activities. This agreement replaces unearned amounts owed by Pfizer under a previous collaboration agreement from July 2021, reflecting a significant strategic shift in the commercialization of VEPPANU.
- : SEC 8-K (1.01): On May 11, 2026, Arvinas, Inc., along with its subsidiaries Arvinas Operations, Inc. and Arvinas Estrogen Receptor, Inc., entered into a License Agreement with Rigel Pharmaceuticals, Inc. Under this agreement, Arvinas and Pfizer Inc. will grant Rigel exclusive global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant), a PROTAC estrogen receptor degrader approved for use as a monotherapy. This strategic partnership is expected to enhance the market reach and therapeutic applications of VEPPANU™, with significant implications for future revenue and collaboration in oncology. The event marks a pivotal expansion in Arvinas's licensing activities and alliances within the pharmaceutical landscape.
Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.
Arvinas funding history
| Date | Round | Amount |
|---|---|---|
| Jul 2019 | Venture | $32.5M |
Leadership
- Jakob Loven, Director
- Liam Ratcliffe, Director
- Briggs Morrison, Director
- Edward Jr., Director
- Timothy Shannon, Director
- Kush Parmar, Director
- Bradley Margus, Director
- John Houston, Executive Officer, Director
- Noah Berkowitz, M.D., Ph.D., Chief Medical Officer
- John Houston, Ph.D., President
- Briggs Morrison, M.D., Chief Executive Officer
- Andrew Saik, Chief Financial Officer
Verified email and direct lines for Arvinas’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.
Employee benefit plans
Arvinas files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Arvinas in the news
- Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) - GlobeNewswire (May 01, 2026)
- Arvinas Shares Novel Oculomotor and Biomarker Data from - GlobeNewswire (Oct 07, 2026)
- Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire (Sep 29, 2026)
- Arvinas Announces First Patient Dosed in Phase 1/2 Clinical - GlobeNewswire (Sep 28, 2026)
- Arvinas to Present at Jefferies Global Healthcare Conference - GlobeNewswire (Nov 11, 2026)
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation - GlobeNewswire (Oct 27, 2026)
- Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 - GlobeNewswire (Oct 27, 2026)
- Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson’s Disease and Movement Disorders® - GlobeNewswire (Oct 01, 2026)
Companies similar to Arvinas
- Celldex · Biotechnology, Health Care, research, Therapeutics
- Rezolute · Biotechnology, Health Care, research, Therapeutics
- Altimmune · Biotechnology, Health Care, research, Therapeutics
- Applied StemCell · Biotechnology, Health Care, research, Therapeutics
- Takis S.r.l · Biotechnology, Health Care, research, Therapeutics
About Arvinas: questions and answers
What does Arvinas do?
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein deg
Where is Arvinas headquartered?
Arvinas is headquartered in New Haven, Connecticut, United States.
How many employees does Arvinas have?
Arvinas has about 430 employees.
Has Arvinas raised funding?
Yes. Fundz has recorded 1 funding event for Arvinas. The most recent, $32.5M, was in Jul 2019.
Who leads Arvinas?
John Houston, Ph.D. is a President at Arvinas.
What is the latest news on Arvinas?
On Jun 22, 2026, Arvinas, Inc. Begins Search for New Chief Medical Officer
Is Arvinas a public company?
Yes. Arvinas is publicly traded under the ticker ARVN.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy